CapForce, Inc. (CFOR)
6.02
-0.88
(-12.75%)
USD |
OTCM |
Nov 05, 16:00
CapForce Debt to Equity Ratio : 0.0264 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0264 |
| March 31, 2026 | 0.0576 |
| December 31, 2025 | 0.0607 |
| September 30, 2025 | 0.2034 |
| June 30, 2025 | 0.2058 |
| March 31, 2025 | 0.2809 |
| December 31, 2024 | 0.2861 |
| September 30, 2024 | 0.7506 |
| June 30, 2024 | -1.154 |
| March 31, 2024 | -1.208 |
| December 31, 2023 | -1.128 |
| September 30, 2023 | 4.690 |
| June 30, 2023 | 1.851 |
| March 31, 2023 | 1.519 |
| December 31, 2022 | 1.957 |
| September 30, 2022 | 1.108 |
| June 30, 2022 | 0.6595 |
| March 31, 2022 | 0.7517 |
| December 31, 2021 | 0.6109 |
| September 30, 2021 | 0.7446 |
| June 30, 2021 | 0.6184 |
| March 31, 2021 | 0.5108 |
| December 31, 2020 | 1.078 |
| September 30, 2020 | 1.255 |
| Date | Value |
|---|---|
| June 30, 2020 | 1.110 |
| March 31, 2020 | 0.1833 |
| December 31, 2019 | 0.736 |
| September 30, 2019 | -2.361 |
| June 30, 2019 | 2.094 |
| March 31, 2019 | 0.9311 |
| December 31, 2018 | 0.5729 |
| September 30, 2018 | 0.4867 |
| June 30, 2018 | 0.3054 |
| March 31, 2018 | 0.1591 |
| December 31, 2017 | 0.9251 |
| September 30, 2017 | 0.3671 |
| June 30, 2017 | -0.9244 |
| March 31, 2017 | 2.305 |
| December 31, 2016 | 0.4277 |
| September 30, 2016 | 0.4556 |
| June 30, 2016 | 0.2055 |
| March 31, 2016 | 0.4653 |
| December 31, 2015 | 0.2176 |
| September 30, 2015 | 0.1294 |
| June 30, 2015 | 0.0376 |
| March 31, 2015 | -0.9293 |
| December 31, 2013 | 2.081 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Phio Pharmaceuticals Corp. | 0.00 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 3.763 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -2.084 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 87.68M |
| Total Liabilities (Quarterly) | 13.40M |
| Shareholders Equity (Quarterly) | 74.28M |
| Current Ratio | 4.273 |
| Net Debt Paydown Yield | 0.00% |